ClinicalTrials.gg
CompletedNCT06664801LIGHTRAYUpdated Dec 5, 2025

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

A Phase 2 interventional study of Sotatercept and Background PAH Therapy in Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed at 98 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.

Enrollment
5th of 18
164 · median 44
Started
2024
with 1 other
Phase 2
7 of 18
3 open now
Registered
11th of 18
by date
Lead sponsor
7 of 18
Merck Sharp & Dohme LLC

Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 5th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 2, and was the 11th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About sotatercept

sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sotatercept in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs.

The goal of the study is to learn:

  • What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this trial.
  • About the safety of sotatercept and if people tolerate it
03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has documented diagnostic Right Heart Catheterization, with the diagnosis of World Health Organization (WHO) Pulmonary Atrial Hypertension (PAH) Group 1 in any of the following subtypes: Idiopathic PAH, Heritable PAH, Drug/toxin-induced PAH, PAH associated with connective tissue disease, PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following repair
  • Has symptomatic PAH classified as WHO Functional Class II or III

Exclusion criteria

Exclusion Criteria:

  • Has a weight of \<35 kg
  • Has a diagnosis of PH WHO Groups 2, 3, 4, or 5
  • Has a diagnosis of the following PAH Group 1 subtypes: -associated PAH, PAH associated with portal hypertension, Exclusion in PAH Group 1 should also include schistosomiasis-associated PAH, pulmonary veno occlusive disease and pulmonary capillary hemangiomatosis
  • Has uncontrolled systemic hypertension
  • Has a history of pneumonectomy
  • Has a history of known pericardial constriction
  • Has a history of restrictive cardiomyopathy
  • Has history of atrial septostomy (within 180 days prior to study start)
  • Has personal or family history of long syndrome
  • Has history of coronary artery disease (myocardial infarction, percutaneous coronary intervention, coronary artery bypass, graft surgery, or cardiac anginal chest pain) (within 6 months prior to study start)
  • Has a cerebrovascular accident (within 3 months prior to study start)
  • Has significant (>2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease
  • Has untreated more than mild obstructive sleep apnea
  • Has known that is progressing or has required active treatment within the past 5 years
  • Has recently started (within 12 months prior to study start) or has plans to start weight loss medication or enter a weight loss program during the study period
  • Has a previous (within 3 years) or planned (during the study) obesity treatment with surgery or a weight-loss device
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    Weight-based sotatercept dosing

    Participants will receive sotatercept via subcutaneous (SC) injection every 3 weeks at an initial dose of 0.3 mg/kg and then at a maintenance dose of 0.7 mg/kg using a weight-based method during a 24-week treatment period. Participants will continue to take their background PAH therapy during the study.

    Biological: Sotatercept · Biological: Background PAH Therapy

  • Experimental
    Weight-banded sotatercept dosing

    Participants will receive sotatercept via SC injection every 3 weeks at an initial dose of up to 45 mg and then at a maintenance dose of up to 90 mg using a weight-banded method during a 24-week treatment period. Participants will continue to take their background PAH therapy during the study.

    Biological: Sotatercept · Biological: Background PAH Therapy

Interventions

  • BiologicalSotatercept

    SC administered every 3 weeks.

    Also known as: MK-7962

  • BiologicalBackground PAH Therapy

    Background PAH therapy may consist of the following drug classes: single, double, or triple combination of therapy with endothelin-receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogs or receptor antagonists

06

What researchers measure

Primary outcomes

  1. Steady-State Average Serum Concentrations of Sotatercept (Cavg)

    Steady-state Cavg of sotatercept will be reported.

    Time frame: Predose and at designated time points post-dose (up to 24 weeks)

  2. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is a health problem that happens or worsens during a study. Number of participants who experience an AE will be reported.

    Time frame: Up to 37 weeks

  3. Number of Participants who Discontinue Study Treatment due to an Adverse Event

    An AE is a health problem that happens or worsens during a study. Number of participants who discontinue study treatment will be reported.

    Time frame: Up to 21 weeks

Secondary outcomes

  1. Initial Dose Average Serum Concentrations of Sotatercept (Cavg)

    Initial dose Cavg of sotatercept will be reported.

    Time frame: Predose and at designated time points post-dose (up to 3 weeks)

07

Study locations

98 sites
  • Pulmonary Associates, PA ( Site 1903)
    Phoenix, Arizona 85032, United States
  • University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 1930)
    Aurora, Colorado 80045, United States
  • Indiana University Health Methodist Hospital ( Site 1905)
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center ( Site 1928)
    Kansas City, Kansas 66160, United States
  • Norton Pulmonary Specialists ( Site 1935)
    Louisville, Kentucky 40202, United States
  • University of New Mexico Health Sciences Center - Department of Internal Medicine ( Site 1916)
    Albuquerque, New Mexico 87131, United States
  • University of Cincinnati Medical Center ( Site 1927)
    Cincinnati, Ohio 45219, United States
  • Ascension Seton Heart Specialty Care and Transplant Center ( Site 1918)
    Austin, Texas 78705, United States
  • Froedtert Hospital & the Medical College of Wisconsin ( Site 1934)
    Milwaukee, Wisconsin 53226, United States
  • Centro Medico Capital ( Site 0002)
    La Plata, Buenos Aires B1904AAW, Argentina
  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0006)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
  • Instituto Medico Rio Cuarto ( Site 0010)
    Río Cuarto, Córdoba Province X5800AEV, Argentina
  • Hospital Britanico de Buenos Aires ( Site 0004)
    CABA, C1280AEB, Argentina
  • Instituto de Cardiologia Juana F. Cabral ( Site 0008)
    Corrientes, W3400AMZ, Argentina
  • Hospital Provincial Jose Maria Cullen ( Site 0005)
    Santa Fe, 3000, Argentina
  • Royal Prince Alfred Hospital ( Site 0103)
    Camperdown, New South Wales 2050, Australia
  • Westmead Hospital ( Site 0100)
    Westmead, New South Wales 2145, Australia
  • Wesley Research Institute ( Site 0101)
    Auchenflower, Queensland 4066, Australia
  • The Alfred Hospital ( Site 0102)
    Melbourne, Victoria 3004, Australia
  • Peter Lougheed Centre ( Site 0203)
    Calgary, Alberta T1Y 6J4, Canada
  • IUCPQ ( Site 0208)
    Québec, Quebec G1V 4G5, Canada
  • Guangdong Provincial People s Hospital ( Site 2000)
    Guangzhou, Guangdong 510080, China
  • The Second Xiangya Hospital of Central South University ( Site 2002)
    Changsha, Hunan 410011, China
  • Shanghai Pulmonary Hospital ( Site 2004)
    Shanghai, Shanghai Municipality 200433, China
  • Yan an Hospital of Kunming City ( Site 2011)
    Kunming, Yunnan 650051, China
  • Clinica Cardio VID ( Site 0307)
    Medellín, Antioquia 050034, Colombia
  • Clinica Colsanitas - Sede Reina Sofia ( Site 0303)
    Bogotá, Bogota D.C. 110111, Colombia
  • Fundacion Santa Fe de Bogota ( Site 0302)
    Bogota, Cundinamarca 110111, Colombia
  • IMAT S.A.S ( Site 0301)
    Montería, Departamento de Córdoba 230002, Colombia
  • Centro de Investigaciones Clinicas SAS ( Site 0306)
    Cali, Valle del Cauca Department 760036, Colombia
  • Clínica Imbanaco S.A.S ( Site 0304)
    Cali, Valle del Cauca Department 760042, Colombia
  • Centrum pro plicní hypertenzi VFN II. interni klinika VFN a 1. LF UK ( Site 0400)
    Prague, Praha 2 128 08, Czechia
  • CHU Bordeaux Haut-Leveque ( Site 0501)
    Pessac, Aquitaine 33604, France
  • Assistance Publique Hôpitaux de Marseille - Hôpital Nord ( Site 0500)
    Marseille, Bouches-du-Rhone 13015, France
  • CHU Dijon Bourgogne ( Site 0502)
    Dijon, Cote-d Or 21079, France
  • CHU de Rouen ( Site 0503)
    Rouen, Haute-Normandie 76000, France
  • CHU GABRIEL MONTPIED ( Site 0504)
    Clermont-Ferrand, Puy-de-Dome 63003, France
  • Thoraxklinik-Heidelberg gGmbH-Zentrum für Pulmonale Hypertonie ( Site 0600)
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • Klinikum der Universität München Großhadern ( Site 0611)
    München, Bavaria 81377, Germany
  • Medizinische Hochschule Hannover ( Site 0604)
    Hanover, Lower Saxony 30625, Germany
  • Universitätsklinikum Bonn ( Site 0608)
    Bonn, North Rhine-Westphalia 53127, Germany
  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0609)
    Berlin, 10117, Germany
  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0610)
    Hamburg, 20246, Germany
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ ( Site 0704)
    Szeged, Csongrád megye 6725, Hungary
  • Pécsi Tudományegyetem Klinikai Központ ( Site 0703)
    Pécs, Pecs 7624, Hungary
  • Semmelweis Egyetem ( Site 0701)
    Budapest, Pest County 1083, Hungary
  • Gottsegen Gyorgy Orszagos Kardiologiai Intezet ( Site 0702)
    Budapest, 1096, Hungary
  • Rambam Health Care Campus ( Site 0802)
    Haifa, 3109601, Israel
  • Carmel Hospital ( Site 0803)
    Haifa, 3436212, Israel
  • Rabin Medical Center ( Site 0805)
    Petah Tikva, 4941492, Israel
  • Sheba Medical Center ( Site 0801)
    Ramat Gan, 5265601, Israel
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 0905)
    Bologna, Emilia-Romagna 40138, Italy
  • AOU Policlinico Umberto I ( Site 0910)
    Rome, Lazio 00161, Italy
  • Ospedale San Martino ( Site 0901)
    Genoa, Liguria 16132, Italy
  • ASST Grande Ospedale Metropolitano Niguarda ( Site 0900)
    Milan, Lombardy 20162, Italy
  • Fondazione IRCCS San Gerardo dei Tintori ( Site 0911)
    Monza, Lombardy 20900, Italy
  • A.O.U. Citta della Salute e della Scienza di Torino ( Site 0904)
    Turin, Piedmont 10126, Italy
  • Azienda Ospedaliera Universitaria Integrata ( Site 0908)
    Verona, Veneto 37126, Italy
  • Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico ( Site 0902)
    Milan, 20122, Italy
  • Fondazione IRCCS Policlinico San Matteo ( Site 0909)
    Pavia, 27100, Italy
  • Fondazione G. Monasterio ( Site 0907)
    Pisa, 56124, Italy
  • Ospedale Civile SS Annunziata ( Site 0903)
    Sassari, 07100, Italy
  • Nagoya University Hospital ( Site 2102)
    Nagoya, Aichi-ken 466-8560, Japan
  • National Cerebral and Cardiovascular Center ( Site 2103)
    Suita, Osaka 564-8565, Japan
  • The University of Tokyo Hospital ( Site 2101)
    Bunkyo, Tokyo 113-8655, Japan
  • Kyorin University Hospital ( Site 2100)
    Mitaka, Tokyo 181-8611, Japan
  • Kyushu University Hospital ( Site 2105)
    Fukuoka, 812-8582, Japan
  • National Hospital Organization Okayama Medical Center ( Site 2104)
    Okayama, 701-1192, Japan
  • Radboud University Medical Center ( Site 1001)
    Nijmegen, Gelderland 6525 GA, Netherlands
  • Sint Antonius Ziekenhuis ( Site 1000)
    Nieuwegein, Utrecht 3435CM, Netherlands
  • Krakowski Szpital Specjalistyczny im. św. Jana Pawła II ( Site 1100)
    Krakow, Lesser Poland Voivodeship 31-202, Poland
  • National University Heart Centre, Singapore ( Site 1200)
    Singapore, Central Singapore 119074, Singapore
  • National Heart Centre Singapore ( Site 1201)
    Singapore, Central Singapore 169609, Singapore
  • Chonnam National University Hospital (CNUH) ( Site 1304)
    Gwangju, Kwangju-Kwangyokshi 61469, South Korea
  • Pusan National University Hospital ( Site 1305)
    Busan, Pusan-Kwangyokshi 49241, South Korea
  • Seoul National University Hospital ( Site 1302)
    Seoul, 03080, South Korea
  • Severance Hospital Yonsei University Health System ( Site 1300)
    Seoul, 03722, South Korea
  • Asan Medical Center ( Site 1303)
    Seoul, 05505, South Korea
  • Samsung Medical Center ( Site 1301)
    Seoul, 06351, South Korea
  • Hospital Universitari Son Espases ( Site 1412)
    Palma, Balearic Islands 07120, Spain
  • Hospital Marques de Valdecilla ( Site 1405)
    Santander, Cantabria 39008, Spain
  • Hospital Clinic de Barcelona ( Site 1406)
    Barcelona, Catalonia 08036, Spain
  • Hospital Vall D Hebron ( Site 1404)
    Barcelona, 08035, Spain
  • Hospital Ramon y Cajal ( Site 1401)
    Madrid, 28034, Spain
  • Hospital General Universitario 12 de Octubre ( Site 1403)
    Madrid, 28041, Spain
  • Hospital Universitario La Paz ( Site 1410)
    Madrid, 28046, Spain
  • Hospital Virgen del Rocio ( Site 1407)
    Seville, 41013, Spain
  • Hospital Universitario de Toledo ( Site 1408)
    Toledo, 45007, Spain
  • Kaohsiung Veterans General Hospital ( Site 1503)
    Kaohsiung City, 813414, Taiwan
  • National Cheng Kung University Hospital ( Site 1501)
    Tainan, 70403, Taiwan
  • Taipei Veterans General Hospital ( Site 1502)
    Taipei, 11217, Taiwan
  • Faculty of Medicine Siriraj Hospital ( Site 1600)
    Bangkok, Bangkok 10700, Thailand
  • Maharaj Nakorn Chiang Mai Hospital ( Site 1601)
    Chiang Mai, 50200, Thailand
  • Royal Papworth Hospital ( Site 1802)
    Cambridge, Cambridgeshire CB2 0AY, United Kingdom
  • Royal Free London NHS Foundation Trust ( Site 1803)
    London, London, City of NW3 2QG, United Kingdom
  • Royal Brompton Hospital ( Site 1804)
    London, London, City of SW3 6NP, United Kingdom
  • Hammersmith Hospital ( Site 1801)
    London, London, City of W12 OHS, United Kingdom
  • Golden Jubilee National Hospital ( Site 1800)
    Glasgow, West Dunbartonshire G81 4DY, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Nov 2025, 12 months.

Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 12 months is below that.

Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Oct 30, 2024
StartActual
Nov 14, 2024
Primary completionActual
Nov 20, 2025
CompletionActual
Nov 20, 2025
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06664801
Responsible party
Sponsor
First posted
Oct 30, 2024
Start date
Nov 14, 2024
Primary completion
Nov 20, 2025
Completion
Nov 20, 2025
Last update
Dec 5, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion